Product-focused roadmap shows how MSC secretomes can become scalable, standardized, GMP-ready biotherapeutics.

Compared with an injection of saline placebo, a single intra-articular injection of autologous adipose-derived mesenchymal stromal cells showed no significant improvement in pain or function scores in ...

RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication. RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and teenagers ...

The US Food and Drug Administration (FDA) has approved remestemcel-L (Ryoncil, Mesoblast Ltd), an allogeneic bone marrow‒derived mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...

Researchers discovered that chronic inflammation fundamentally remodels the bone marrow, allowing mutated stem cell clones to quietly gain dominance with age. Reprogrammed stromal cells and interferon ...